Wall Street analyst estimates for Femasys Inc. (FEMY): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-17 | $-0.47 | ||
| 2026-08-14 | $-1.33 | $-1.31 | -1.5% |
| 2026-05-08 | $0.10 | $-1.33 | +107.4% |
| 2026-03-26 | $-1.25 | $-1.67 | +24.8% |
| 2025-11-11 | $-2.00 | $-2.30 | +13.0% |
| 2025-08-08 | $-3.20 | $-3.27 | +2.0% |
| 2025-05-08 | $-4.60 | $-3.40 | -35.3% |
| 2025-03-27 | $-4.60 | $-3.70 | -24.3% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $929064 | $1.0M | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Cost of Revenue | $223678 | $306533 | $370384 | $441938 | $380069 | $544903 | $872400 |
| Gross Profit | $705386 | $731385 | $809305 | $764280 | $691901 | $1.1M | $1.4M |
| Research & Development | $6.9M | $4.1M | $4.1M | $5.8M | $7.2M | $8.2M | $7.6M |
| Selling, General & Admin | $4.8M | $2.9M | $4.5M | $6.0M | $7.5M | $10.4M | $11.1M |
| Operating Expenses | $12.3M | $7.7M | $9.1M | $12.4M | $15.2M | $18.9M | $19.0M |
| Operating Income | -$11.6M | -$6.9M | -$8.3M | -$11.6M | -$14.5M | -$17.8M | -$17.6M |
| EBITDA | -$10.2M | -$5.8M | -$6.6M | -$10.5M | -$13.2M | -$16.3M | -$15.9M |
| Interest Expense | $9972 | $12553 | $19226 | $13464 | $165390 | $1.6M | $1.9M |
| Pre-tax Income | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| Income Tax | $3006 | $1800 | $4000 | $6300 | $4338 | $9602 | $1297 |
| Net Income | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| EPS | $-19.20 | $-11.80 | $-12.80 | $-19.40 | $-18.60 | $-16.80 | $-9.40 |
| EPS (Diluted) | $-19.20 | $-11.80 | $-12.80 | $-19.40 | $-18.60 | $-16.80 | $-9.40 |
| Shares Outstanding (Diluted) | $588078 | $588078 | $590208 | $590208 | $769219 | $1.1M | $2.0M |
Price
| Price | $2.54 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AIMD · APLM · BCTX · COCH · CRIS · DARE · EKSO
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of FEMY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks